Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats. 1993

R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
Department of Geriatric Medicine, Osaka University Medical School, Japan.

Recent studies suggest the linkage of hypertension and insulin resistance. High fructose diet is known to induce hyperinsulinemia and hypertension in rats. In a previous study, however, high fructose (66%) diet failed to elevate blood pressure but increased left ventricular weight in Sprague-Dawley rats. In the present study, we investigated the precise mechanism of high fructose diet-induced changes in the cardiovascular system in rats. Intake of fructose-enriched diet for 2 weeks increased serum insulin and plasma angiotensin II levels. Urinary excretion of sodium and norepinephrine was not changed. Blood pressure measured directly through an indwelling catheter was not increased, but left ventricular weight and protein content were increased by high fructose diet. To further elucidate the role of the renin-angiotensin system, an angiotensin II type 1 receptor antagonist, TCV-116, was given orally at 1 mg/kg per day with either normal or high fructose diet. Concomitant administration of TCV-116 did not affect plasma glucose or serum insulin levels. Plasma angiotensin II was increased, but neither urinary sodium nor norepinephrine was changed by TCV-116. TCV-116 similarly decreased blood pressure in rats on normal and high fructose diets. Increase in left ventricular weight induced by high fructose diet was prevented by the concomitant administration of TCV-116. On the other hand, left ventricular weight in control rats was not changed by TCV-116. In conclusion, increased plasma angiotensin II may account for the left ventricular hypertrophy induced by high fructose diet, whereas hemodynamic change, sodium retention, and the sympathetic nervous system do not play an important role.

UI MeSH Term Description Entries
D008297 Male Males
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D013777 Tetrazoles

Related Publications

R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
June 1992, Hypertension (Dallas, Tex. : 1979),
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
February 2001, American journal of hypertension,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
February 1999, Journal of molecular and cellular cardiology,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
January 2005, Current medicinal chemistry. Cardiovascular and hematological agents,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
March 2001, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
September 1991, Circulation research,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
March 2000, Circulation research,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
November 1997, Journal of molecular and cellular cardiology,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
November 1996, Journal of human hypertension,
R Kobayashi, and M Nagano, and F Nakamura, and J Higaki, and Y Fujioka, and H Ikegami, and H Mikami, and N Kawaguchi, and S Onishi, and T Ogihara
October 1999, Canadian journal of physiology and pharmacology,
Copied contents to your clipboard!